Email Updates

Search form

You are here

Browse and Order Resources

AVAC's 2018 annual state of the field report, No Prevention, No End! looks at today's prevention crisis and offers context, analysis and strategy to turn that crisis around.

October 2018
AVAC
AVAC Report

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion (Figure 2). This is the fifth consecutive year of decreasing annual investment, with 2017 levels representing the lowest funding since 2005.

October 2018
The Resource Tracking for HIV Prevention R&D Working Group
AVAC
IAVI
Report/Issue Brief

This four-pager explores stories about stakeholder engagement in the current suite of efficacy trials as well as stories around global support for vaccine research in the age of an expanded HIV prevention landscape.

May 2018
AVAC
Report/Issue Brief

In the new issue of Px Wire, AVAC gives our take on this year’s PEPFAR process for establishing the Country Operational Plans (COPs). These plans define what work will be done with PEPFAR money at the country level and how that work will be evaluated in each of the 63 countries that receive PEPFAR money.

May 2018
AVAC
Px Wire

PrEP works if you take it. The figures on this graphic show the relationship between PrEP efficacy and adherence and the status of regulatory action on PrEP worldwide. It also shows other potential new formulations of ARV-based prevention being evaluated as additional options in the future.

August 2016
AVAC
By The Numbers
Infographic

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.

May 2016
AVAC
By The Numbers
Infographic

The term “microbicide” refers to substances being studied that could be used in the vagina and/or rectum to reduce the risk of HIV infection via sexual exposure. There are no licensed microbicides available today. Simple, easy-to-use microbicides would help these individuals take control of their own health—while offering people everywhere an additional, needed option. The graphics below represent key facts about the microbicide field.

July 2016
AVAC
By The Numbers
Infographic

A handbook designed to guide the user through various communication scenarios. The handbook offers tips and strategies to navigating difficult scenarios that may occur throughout the clinical trial process. It also offers suggestions on routine scenarios such as result dissemination and training staff and spokespersons.

February 2014
FHI 360
Handbook/Manual
Training Material

A comprehensive 2012 report from civil society about the state of voluntary medical male circumcision in Africa. Includes priority recommendations and in-depth discussion of factors influencing national scale-up efforts.  

July 2012
AVAC
National Empowerment Network of People Living with HIV/AIDS in Kenya
Sonke Gender Justice Network
Uganda Network of AIDS Service Organizations
Report/Issue Brief

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials. This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

June 2011
AVAC
UNAIDS
Handbook/Manual
Training Material

Pages